Search Results

Terumo Acquires Onset Medical

January 16, 2012—Terumo Medical Corporation (Somerset, NJ) announced the acquisition of Onset Medical Corporation (Irvine, CA).

Terumo Provides Update on Operations in Japan

March 25, 2011—Terumo Interventional Systems (Somerset, NJ), a subsidiary of Terumo Corporation (Tokyo, Japan), issued a statement addressing the company's operations and outreach efforts following the March 11 earthquake and tsunami disasters in Japan.

Terumo Launches Detachable Azur CX Peripheral Coil System

October 8, 2013—Terumo Interventional Systems (Somerset, NJ) announced the launch of its Azur CX peripheral coil system in the United States at the VIVA 2013: Vascular Interventional Advances conference, which is being held October 8 to 11 in Las Vegas, Nevada.

Terumo Provides Update on Operations Following Earthquake and Tsunami

March 25, 2011—Terumo Interventional Systems (Somerset, NJ), a subsidiary of Terumo Corporation (Tokyo, Japan), issued a statement addressing the company's operations and outreach efforts following the March 11 earthquake and tsunami disasters in Japan.

Terumo Interventional Systems Launches Pinnacle Precision Access System

October 26, 2012—Terumo Interventional Systems (Somerset, NJ) announced the nationwide availability of its new Pinnacle Precision Access System, which is designed for smooth, efficient, and reliable vascular access.

Terumo's Misago Stent to Be Studied in US and Japan

May 12, 2010—Terumo Medical Corporation (Somerset, NJ) announced it has received an investigational device exemption conditional approval from the US Food and Drug Administration for OSPREY (Occlusive/Stenotic Peripheral Artery Revascularization Study), which will evaluate the safety and effectiveness of the Misago selfexpanding stent system for use in the superficial femoral artery.

Terumo's Misago Stent to Be Jointly Studied in US and Japan

May 12, 2010—Terumo Medical Corporation (Somerset, NJ) announced it has received an investigational device exemption conditional approval from the US Food and Drug Administration for OSPREY (Occlusive/Stenotic Peripheral Artery Revascularization Study), which will evaluate the safety and effectiveness of the Misago self-expanding stent system for use in the superficial femoral artery. The Misago system, which is commercially available in Europe, consists of a nitinol stent that is premounted on the distal portion of a rapid-exchange delivery catheter.

US Enrollment Begins in OSPREY Study of Terumo's Misago SFA Stent

September 13, 2010—Terumo Interventional Systems (Somerset, NJ) announced the first United States patient implant in the OSPREY (Occlusive/Stenotic Peripheral Artery Revascularization Study) trial, which will evaluate the safety and efficacy of the company's Misago peripheral self-expanding stent system for use in the superficial femoral artery (SFA).